NasdaqGS - Nasdaq Real Time Price USD

AstraZeneca PLC (AZN)

Compare
66.40 +0.77 (+1.17%)
At close: November 25 at 4:00 PM EST
66.55 +0.15 (+0.23%)
Pre-Market: 8:22 AM EST
Loading Chart for AZN
DELL
  • Previous Close 65.63
  • Open 65.92
  • Bid 66.34 x 400
  • Ask 66.46 x 400
  • Day's Range 65.86 - 66.57
  • 52 Week Range 60.47 - 87.68
  • Volume 5,080
  • Avg. Volume 5,406,048
  • Market Cap (intraday) 205.881B
  • Beta (5Y Monthly) 0.18
  • PE Ratio (TTM) 31.92
  • EPS (TTM) 2.08
  • Earnings Date Feb 6, 2025
  • Forward Dividend & Yield 1.49 (2.24%)
  • Ex-Dividend Date Aug 9, 2024
  • 1y Target Est 88.27

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

www.astrazeneca.com

89,900

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AZN

View More

Performance Overview: AZN

Trailing total returns as of 11/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AZN
0.72%
FTSE 100
7.10%

1-Year Return

AZN
5.17%
FTSE 100
10.61%

3-Year Return

AZN
25.87%
FTSE 100
13.30%

5-Year Return

AZN
53.67%
FTSE 100
11.98%

Compare To: AZN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AZN

View More

Valuation Measures

Annual
As of 11/25/2024
  • Market Cap

    204.47B

  • Enterprise Value

    231.10B

  • Trailing P/E

    32.00

  • Forward P/E

    14.16

  • PEG Ratio (5yr expected)

    0.72

  • Price/Sales (ttm)

    4.05

  • Price/Book (mrq)

    5.06

  • Enterprise Value/Revenue

    4.51

  • Enterprise Value/EBITDA

    15.54

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.68%

  • Return on Assets (ttm)

    8.50%

  • Return on Equity (ttm)

    16.66%

  • Revenue (ttm)

    51.21B

  • Net Income Avi to Common (ttm)

    6.5B

  • Diluted EPS (ttm)

    2.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.93B

  • Total Debt/Equity (mrq)

    77.47%

  • Levered Free Cash Flow (ttm)

    9.51B

Research Analysis: AZN

View More

Company Insights: AZN

Research Reports: AZN

View More

People Also Watch